Qdenga is a vaccine that helps protect against dengue disease. The vaccine can be given to adults, adolescents and children from 4 years of age. Dengue disease is a mosquito-borne tropical disease caused by the dengue virus, leading to mild, flu-like symptoms in most people. However, a small number of patients develop severe disease, with potentially fatal bleeding and organ damage. This vaccine contains attenuated (weakened) versions of dengue virus serotypes (varieties) 1, 2, 3 and 4.
Therapeutic Indication
### Therapeutic indication Qdenga is indicated for the prevention of dengue disease in individuals from 4 years of age. The use of Qdenga should be in accordance with official recommendations.
Therapeutic Area (MeSH)
ATC Code
J07BX04
ATC Item
dengue virus vaccines
Pharmacotherapeutic Group
Vaccines
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| Dengue virus, serotype 2, expressing Dengue virus, serotype 4, surface proteins, live, attenuated | N/A | dengue virus, serotype 2, expressing dengue virus, serotype 4, surface proteins, live, attenuated |
| Dengue virus, serotype 2, expressing Dengue virus, serotype 1, surface proteins, live, attenuated | N/A | Dengue virus 1 Live Virus Human Challenge (subcutaneous, Dengue) |
| Dengue virus, serotype 2, expressing Dengue virus, serotype 3, surface proteins, live, attenuated | N/A | dengue virus vaccines |
| Dengue virus, serotype 2, live, attenuated | N/A | Cyd dengue virus serotype 2 live (attenuated) antigen |
EMA Name
Qdenga
Medicine Name
Qdenga
Aliases
N/A
